- Home
- APLT vs CCEL Comparison
APLT vs CCEL Comparison
Compare APLT & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- CCEL
- Stock Information
- Founded
- APLT 2016
- CCEL 1989
- Country
- APLT United States
- CCEL United States
- Employees
- APLT N/A
- CCEL N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- APLT Health Care
- CCEL Health Care
- Exchange
- APLT Nasdaq
- CCEL Nasdaq
- Market Cap
- APLT 44.0M
- CCEL 39.9M
- IPO Year
- APLT 2019
- CCEL 1997
- Fundamental
- Price
- APLT $0.45
- CCEL $4.75
- Analyst Decision
- APLT Buy
- CCEL Strong Buy
- Analyst Count
- APLT 7
- CCEL 1
- Target Price
- APLT $6.10
- CCEL $8.50
- AVG Volume (30 Days)
- APLT 1.6M
- CCEL 7.9K
- Earning Date
- APLT 08-11-2025
- CCEL 07-15-2025
- Dividend Yield
- APLT N/A
- CCEL 12.47%
- EPS Growth
- APLT N/A
- CCEL N/A
- EPS
- APLT N/A
- CCEL N/A
- Revenue
- APLT $265,000.00
- CCEL $31,988,783.00
- Revenue This Year
- APLT $415.60
- CCEL $1.75
- Revenue Next Year
- APLT $1,323.96
- CCEL N/A
- P/E Ratio
- APLT N/A
- CCEL N/A
- Revenue Growth
- APLT N/A
- CCEL 1.10
- 52 Week Low
- APLT $0.30
- CCEL $4.68
- 52 Week High
- APLT $10.62
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- APLT 53.55
- CCEL 43.86
- Support Level
- APLT $0.46
- CCEL $4.80
- Resistance Level
- APLT $0.54
- CCEL $5.24
- Average True Range (ATR)
- APLT 0.05
- CCEL 0.28
- MACD
- APLT -0.00
- CCEL -0.00
- Stochastic Oscillator
- APLT 53.66
- CCEL 11.29
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.